Vincent Rondeau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Vincent Rondeau has a total of 142 co-authors. Here are the top co-authors by number of shared publications:
- Mark David Minden
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
18 shared publications - John E. Dick
Department of Molecular Genetics, University of Toronto
17 shared publications - Aarushi Gupta
Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
16 shared publications - Andreas Trumpp
German Cancer Research Center (DKFZ), Heidelberg, Germany
16 shared publications - Andy G. X. Zeng
Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
16 shared publications - Caitlyn Vlasschaert
Queen's University
16 shared publications
Latest Publications
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
Tet2het dendritic cells do not costimulate CD8 T cells more potently than their wild type counterparts
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
Tet2het dendritic cells do not costimulate CD8 T cells more potently than their wild type counterparts
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
TET2-CH colorectal and melanoma cancer patients show enhanced immune infiltration
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
TET2-CH colorectal and melanoma cancer patients show enhanced immune infiltration
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
CH mutational profile of immunotherapy-treated melanoma patients
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
CH mutational profile of immunotherapy-treated melanoma patients
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
In isotype-control condition, Tet2het TILs are enriched for B cells, naïve CD4 and naïve CD8 T Cells, and MDSCs
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
In isotype-control condition, Tet2het TILs are enriched for B cells, naïve CD4 and naïve CD8 T Cells, and MDSCs
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
CH mutational profile of NCT02644359 patients
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
CH mutational profile of NCT02644359 patients
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
Mice with 20% Tet2-mutant hematopoiesis do not show an attenuation of tumor growth in immunotherapy response rate
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
Mice with 20% Tet2-mutant hematopoiesis do not show an attenuation of tumor growth in immunotherapy response rate
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
Tet2het cells composed the majority of stem and progenitor cells in competitive transplantation experiments
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
Tet2het cells composed the majority of stem and progenitor cells in competitive transplantation experiments
- Open Access
- 16 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
Mice with 20% Tet2-mutant hematopoiesis do not show an attenuation of tumor growth in immunotherapy response rate
- 16 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
Mice with 20% Tet2-mutant hematopoiesis do not show an attenuation of tumor growth in immunotherapy response rate
- Open Access
- 16 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
Tet2het cells composed the majority of stem and progenitor cells in competitive transplantation experiments
- 16 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
Tet2het cells composed the majority of stem and progenitor cells in competitive transplantation experiments
- Open Access
- 16 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
In isotype-control condition, Tet2het TILs are enriched for B cells, naïve CD4 and naïve CD8 T Cells, and MDSCs
- 16 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
In isotype-control condition, Tet2het TILs are enriched for B cells, naïve CD4 and naïve CD8 T Cells, and MDSCs